Halozyme Buys Antares, Expanding Drug Delivery Ambitions
Executive Summary
Halozyme will pay $960m to acquire Antares, gaining an auto-injector drug delivery platform, which the company said has broad licensing potential, as well as a commercial portfolio.
You may also be interested in...
Teva’s Partner Antares Swallowed Up By Halozyme In $960m Deal
For just shy of $1bn, Halozyme Therapeutics is set to acquire drug development and injectable technology specialist Antares Pharma, providing it with a portfolio and pipeline of Teva products through a long-term partnership.
Antares sinks on FDA safety data request
Shares of Antares Pharma dropped more than 11% in morning trading on 13 January after the company revealed the FDA wants the firm to create a larger safety database for its experimental drug QuickShot Testosterone after a single reported case of hives in a Phase II study participant.
Antares Pharma names new CFO
New Jersey-based Antares Pharma, which develops self-administered parenteral pharmaceutical products, has named James E Fickenscher senior vice-president and chief financial officer. Mr Fickenscher has more than 25 years of experience in the pharmaceutical industry. Most recently, he was chief financial officer of Auxilium Pharmaceuticals from May 2005 until August 2014.